Stockscreener 앱 받기
4.63
4.99%
0.22
시간 외 거래:
4.63
전일 마감가:
$4.41
열려 있는:
$4.46
하루 거래량:
10.57M
Relative Volume:
0.26
시가총액:
$2.38B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-2.9871
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
+11.03%
1개월 성능:
-21.66%
6개월 성능:
+5.35%
1년 성능:
-27.43%
1일 변동 폭
$4.40
$4.645
1주일 범위
$4.145
$4.645
52주 변동 폭
$3.79
$12.36
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.63 | 2.30B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Costco, AMD, Recursion Pharmaceuticals, Cipher Mining And Snowflake: Why These 5 Stocks Are On Investors' Radars Today - AOL.com
Recursion Pharmaceuticals Gains Traction with Strategic Developments - timothysykes.com
Recursion Pharmaceuticals’ Advances Boost Market Confidence - timothysykes.com
Tangible book value per share of Recursion Pharmaceuticals, Inc. Class A – BIVA:RXRX - TradingView
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock - AOL.com
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
CFO Taylor Surrenders 2,271 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView
[Form 4] RECURSION PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Recursion Pharmaceuticals registers 7.1 million shares for Tempus AI resale By Investing.com - Investing.com Nigeria
Recursion Pharmaceuticals registers 7.1 million shares for Tempus AI resale - Investing.com
Recursion Pharmaceuticals Registers Resale of 7 Million Shares - TipRanks
Recursion Pharmaceuticals Registers Resale of Tempus Shares - TradingView
[8-K] RECURSION PHARMACEUTICALS, INC. Reports Material Event | RXRX SEC FilingForm 8-K - Stock Titan
Form 424B7 RECURSION PHARMACEUTICAL - StreetInsider
RXRX files prospectus for Tempus AI resale of 7.09M shares - Stock Titan
Is the Market Bullish or Bearish on Recursion Pharmaceuticals Inc? - Benzinga
A Look at Recursion Pharmaceuticals’s Valuation Following New CEO, Narrowed Losses, and Milestone Partnership Payment - Yahoo Finance
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - MSN
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? - The Globe and Mail
Recursion Pharmaceuticals (RXRX): Evaluating Valuation After Fresh Leadership, Pharma Partnerships, and Market Optimism - simplywall.st
Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025 - ts2.tech
Top Biotech Stocks To Watch TodayNovember 21st - MarketBeat
Recursion (RXRX) Jumps 8% on Bargain-Hunting - Finviz
Recursion Pharmaceuticals (RXRX) Stock: CEO Sells $5.8 Million in Shares Following Exscientia Merger - CoinCentral
Recursion Pharmaceuticals Surpasses Third-Quarter Expectations, Announces Milestone with Roche - StocksToTrade
Recursion Pharmaceuticals Surges Amid CEO Transition and Strong Q3 Results - StocksToTrade
Soaring Stock: Recursion Pharmaceuticals’ Latest Surge - timothysykes.com
Recursion seeks to deliver results, and a VC sees a wave of M&A coming - statnews.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Q3 Earnings Miss - Quiver Quantitative
Is Recursion Pharmaceuticals Inc. (RXRX) One of the Best Mid Cap Stocks to Buy According to Hedge Funds? - Finviz
Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results - statnews.com
Recursion’s Khan Era: Proving AI Can Crack Drug Discovery - WebProNews
RXRX’s Anemic Revenue Misses Estimates - timothysykes.com
How Recursion Pharmaceuticals Inc. stock trades during market volatilityQuarterly Profit Report & Capital Efficiency Focused Strategies - newser.com
CFO Taylor Surrenders 11,908 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView
Is Recursion Pharmaceuticals a Meme Stock? - MSN
How Recursion Pharmaceuticals Inc. stock reacts to bond yields2025 Biggest Moves & Trade Opportunity Analysis Reports - newser.com
CEO Gibson Files To Sell 40,000 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView
Is Recursion Pharmaceuticals Inc. stock poised for growth2025 Analyst Calls & Fast Entry High Yield Stock Tips - newser.com
Recursion Pharmaceuticals (RXRX) Is Down 11.7% After Revenue Miss and CEO Transition – Has the Bull Case Changed? - simplywall.st
Will earnings trigger a reversal in Recursion Pharmaceuticals Inc.Analyst Downgrade & High Yield Stock Recommendations - newser.com
Recursion Pharmaceuticals, Inc.Class A Common Stock (NQ: RXRX - Markets Financial Content
Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader? (RXRX) - Seeking Alpha
Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday? - MSN
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
1.13%
자본화:
|
볼륨(24시간):